ACSS2 and breast carcinoma: Tamoxifen can induce increased ACSS2 expression in breast cancer cells, leading to treatment resistance, and the combination of ACSS2 inhibitors can reverse this resistance, thereby increasing tamoxifen-induced cell death (Calhoun et al., 2022).